throbber
HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`
`TOVIAZ safely and effectively. See full prescribing information for
`TOVIAZ.
`
`Toviaz® (fesoterodine fumarate)
`For oral administration
`Initial U.S. Approval: 2008
`
`----------------------------RECENT MAJOR CHANGES--------------------------
`Warnings and Precautions: Concomitant Administration with
`
`10/2011
`CYP3A4 Inhibitors (5.8)
`
`
`
`
`Warnings and Precautions: Central Nervous System Effects (5.5) 8/2012
`----------------------------INDICATIONS AND USAGE---------------------------
`Toviaz is a muscarinic antagonist indicated for the treatment of overactive
`
`
`bladder with symptoms of urge urinary incontinence, urgency, and frequency.
`(1)
`
`----------------------DOSAGE AND ADMINISTRATION-----------------------
`
`The recommended starting dose of Toviaz is 4 mg once daily. Based upon
`
`individual response and tolerability, the dose may be increased to 8 mg once
`
`daily. (2)
`
`
`The daily dose of Toviaz should not exceed 4 mg in the following
`
`populations:
`
` Patients with severe renal impairment (CL CR <30 mL/min) (2)
`
`
` Patients taking potent CYP3A4 inhibitors, such as ketoconazole,
`
`itraconazole, and clarithromycin. (2)
`Toviaz is not recommended for use in patients with severe hepatic impairment
`
`(Child-Pugh C). (2)
`Toviaz should be taken with liquid and swallowed whole. Toviaz can be
`
`administered with or without food, and should not be chewed, divided, or
`
`crushed. (2)
`---------------------DOSAGE FORMS AND STRENGTHS----------------------
`
`Toviaz 4 mg extended-release tablets are light blue, oval, biconvex, film-
`
`
`coated, and engraved with “FS” on one side. (3)
`
`
`
`Toviaz 8 mg extended-release tablets are blue, oval, biconvex, film-coated,
`
`
`and engraved with “FT” on one side. (3)
`
`-------------------------------CONTRAINDICATIONS------------------------------
`Toviaz is contraindicated in patients with urinary retention, gastric retention,
`
`or uncontrolled narrow-angle glaucoma. Toviaz is also contraindicated in
`_________________________________________________________________________________________________________
`
`
`
`patients with known hypersensitivity to the drug or its ingredients or to
`
`tolterodine tartrate tablets or tolterodine tartrate extended-release capsules. (4)
`-----------------------WARNINGS AND PRECAUTIONS------------------------
`
` Angioedema of the face, lips, tongue, and/or larynx has been reported with
`
`
`fesoterodine. (5.1).
` Toviaz should be administered with caution to patients with clinically
`significant bladder outlet obstruction because of the risk of urinary retention.
`(5.2)
`
` Toviaz, like other antimuscarinic drugs, should be used with caution in
`
`patients with decreased gastrointestinal motility, such as those with severe
`
`constipation. (5.3)
` Toviaz should be used with caution in patients being treated for narrow-
`angle glaucoma, and only where the potential benefits outweigh the risks
`(5.4)
`
` Central Nervous System Effects: Somnolence has been reported with
`Toviaz. Advise patients not to drive or operate heavy machinery until they
`
`know how Toviaz affects them (5.5)
`
` Toviaz should be used with caution in patients with myasthenia gravis, a
`disease characterized by decreased cholinergic activity at the neuromuscular
`
`junction. (5.9)
`------------------------------ADVERSE REACTIONS-------------------------------
`The most frequently reported adverse events (≥4%) for Toviaz were: dry
`mouth (placebo, 7%; Toviaz 4 mg, 19%; Toviaz 8 mg, 35%) and constipation
`(placebo, 2%; Toviaz 4 mg, 4%; Toviaz 8 mg, 6%). (6)
`To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at
`1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
`
`-----------------------USE IN SPECIFIC POPULATIONS------------------------
`
` Pregnancy and Nursing Mothers: Toviaz should be used during pregnancy
`
`only if the potential benefit outweighs the potential risk to the fetus. (8.1)
`Toviaz should not be administered during nursing unless the potential
`benefit outweighs the potential risk to the neonate. (8.3)
`
` Pediatric Use: The safety and effectiveness of Toviaz in pediatric patients
`
`have not been established. (8.4)
`
`
`See 17 for PATIENT COUNSELING INFORMATION and FDA-
`approved patient labeling.
`
`
`
`
`
`
`
`Revised: 08/2012
`
`
`
`
`
`
`
`
`
`7.8 Drug-Laboratory Test Interactions
`
`8 USE IN SPECIFIC POPULATIONS
`
`8.1 Pregnancy
`
`8.3 Nursing Mothers
`8.4 Pediatric Use
`8.5 Geriatric Use
`8.6 Renal Impairment
`8.7 Hepatic Impairment
`8.8 Gender
`
`
`8.9 Race
`10 OVERDOSAGE
`
`11 DESCRIPTION
`12 CLINICAL PHARMACOLOGY
`
`12.1 Mechanism of Action
`12.2 Pharmacodynamics
`12.3 Pharmacokinetics
`
`
`13 NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`
`14 CLINICAL STUDIES
`16 HOW SUPPLIED/STORAGE AND HANDLING
`
`17 PATIENT COUNSELING INFORMATION
`17.1 Information for Patients
`17.2 FDA-Approved Patient Labeling
`
`
`
`
`
`*Sections or subsections omitted from the full prescribing information are not
`
`listed.
`
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`
`1
`INDICATIONS AND USAGE
`2 DOSAGE AND ADMINISTRATION
`
`3 DOSAGE FORMS AND STRENGTHS
`4 CONTRAINDICATIONS
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Angioedema
`
`5.2 Bladder Outlet Obstruction
`5.3 Decreased Gastrointestinal Motility
`5.4 Controlled Narrow-Angle Glaucoma
`
`5.5 Central Nervous Systems Effects
`5.6 Hepatic Impairment
`5.7 Renal Impairment
`5.8 Concomitant Administration with CYP3A4 Inhibitors
`5.9 Myasthenia Gravis
`
`
`6 ADVERSE REACTIONS
`6.1 Clinical Trials Experience
`
`6.2 Post-marketing Experience
`
`7 DRUG INTERACTIONS
`7.1 Antimuscarinic Drugs
`7.2 CYP3A4 Inhibitors
`7.3 CYP3A4 Inducers
`7.4 CYP2D6 Inhibitors
`7.5 Drugs Metabolized by Cytochrome P450 Isoenzymes
`
`
`7.6 Oral Contraceptives
`
`
`7.7 Warfarin
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 1
`
`

`

`FULL PRESCRIBING INFORMATION
`
`
`1 INDICATIONS AND USAGE
`
`Toviaz® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge
`urinary incontinence, urgency, and frequency.
`
`2 DOSAGE AND ADMINISTRATION
`
`
`
`The recommended starting dose of Toviaz is 4 mg once daily. Based upon individual response and tolerability,
`the dose may be increased to 8 mg once daily.
`The daily dose of Toviaz should not exceed 4 mg in the following populations:
` Patients with severe renal impairment (CLCR <30 mL/min).
` Patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin.
`
` Toviaz is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) [see Warnings
` and Precautions (5.6, 5.8, 5.9); Use in Specific Populations (8.6, 8.7); and Drug Interactions (7.2)].
`
`
`Toviaz should be taken with liquid and swallowed whole. Toviaz can be administered with or without food, and
`should not be chewed, divided, or crushed.
`
`3 DOSAGE FORMS AND STRENGTHS
`
`
`
`
`
`
`
`Toviaz (fesoterodine fumarate) extended-release tablets 4 mg are light blue, oval, biconvex, film-coated, and
`engraved with “FS” on one side.
`
`Toviaz (fesoterodine fumarate) extended-release tablets 8 mg are blue, oval, biconvex, film-coated, and
`engraved with “FT” on one side.
`
`4 CONTRAINDICATIONS
`
`Toviaz is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle
`glaucoma. Toviaz is also contraindicated in patients with known hypersensitivity to the drug or its ingredients,
`or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules [see Clinical Pharmacology
`(12.1)].
`
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Angioedema: Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine. In
`
`some cases angioedema occurred after the first dose. Angioedema associated with upper airway swelling may
`be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, fesoterodine should be
`promptly discontinued and appropriate therapy and/or measures to ensure a patent airway should be promptly
`provided.
`
`5.2 Bladder Outlet Obstruction: Toviaz should be administered with caution to patients with clinically
`
`significant bladder outlet obstruction because of the risk of urinary retention [see Contraindications (4)].
`
`
`
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 2
`
`

`

` 5.3 Decreased Gastrointestinal Motility: Toviaz, like other antimuscarinic drugs, should be used with
`
`
` caution in patients with decreased gastrointestinal motility, such as those with severe constipation.
`
`
`5.4 Controlled Narrow-Angle Glaucoma: Toviaz should be used with caution in patients being treated for
`
`
`
`narrow-angle glaucoma, and only where the potential benefits outweigh the risks [see Contraindications (4)].
`
`5.5 Central Nervous System Effects: Toviaz is associated with anticholinergic central nervous sytem (CNS)
`effects [see Adverse Reactions (6.2)]. A variety of CNS anticholinergic effects have been reported, including
`headache, dizziness, and somnolence. Patients should be monitored for signs of anticholinergic CNS effects,
`particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy
`machinery until they know how Toviaz affects them. If a patient experiences anticholinergic CNS effects, dose
`
`reduction or drug discontinuation should be considered.
`
`5.6 Hepatic Impairment: Toviaz has not been studied in patients with severe hepatic impairment and
`
`
`therefore is not recommended for use in this patient population [see Use in Specific Populations (8.7) and
`
`Dosage and Administration (2)].
`
`5.7 Renal Impairment: Doses of Toviaz greater than 4 mg are not recommended in patients with severe renal
`
`
`impairment [see Use In Specific Populations (8.6) and Dosage and Administration (2)].
`
`5.8 Concomitant Administration with CYP3A4 Inhibitors: Doses of Toviaz greater than 4 mg are not
`recommended in patients taking a potent CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin).
`No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (e.g., erythromycin,
`fluconazole, diltiazem, verapamil and grapefruit juice).
`While the effect of weak CYP3A4 inhibitors (e.g. cimetidine) was not examined by clinical study, some
`
`pharmacokinetic interaction is expected, albeit less than that observed with moderate CYP3A4 inhibitors [see
`
`Drug Interactions (7.2) and Dosage and Administration (2)].
`
`
`
`5.9 Myasthenia Gravis: Toviaz should be used with caution in patients with myasthenia gravis, a disease
`
`
`
`characterized by decreased cholinergic activity at the neuromuscular junction.
`
`
`6 ADVERSE REACTIONS
`
`6.1 Clinical Trials Experience: The safety of Toviaz was evaluated in Phase 2 and 3 controlled trials in a total
`of 2859 patients with overactive bladder, of which 2288 were treated with fesoterodine. Of this total, 782
`received Toviaz 4 mg/day, and 785 received Toviaz 8 mg/day in Phase 2 or 3 studies with treatment periods of
`8 or 12 weeks. Approximately 80% of these patients had >10 weeks exposure to Toviaz in these trials.
`A total of 1964 patients participated in two 12-week, Phase 3 efficacy and safety studies and subsequent open-
`label extension studies. In these two studies combined, 554 patients received Toviaz 4 mg/day and 566 patients
`received Toviaz 8 mg/day.
`In Phase 2 and 3 placebo-controlled trials combined, the incidences of serious adverse events in patients
`receiving placebo, Toviaz 4 mg, and Toviaz 8 mg were 1.9%, 3.5%, and 2.9%, respectively. All serious adverse
`events were judged to be not related or unlikely to be related to study medication by the investigator, except for
`four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis,
`and QT prolongation on ECG.
`The most commonly reported adverse event in patients treated with Toviaz was dry mouth. The incidence of dry
`mouth was higher in those taking 8 mg/day (35%) and in those taking 4 mg/day (19%), as compared to placebo
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 3
`
`

`

`(7%). Dry mouth led to discontinuation in 0.4%, 0.4%, and 0.8% of patients receiving placebo, Toviaz 4 mg,
`and Toviaz 8 mg, respectively. For those patients who reported dry mouth, most had their first occurrence of the
`event within the first month of treatment.
`The second most commonly reported adverse event was constipation. The incidence of constipation was 2% in
`those taking placebo, 4% in those taking 4 mg/day, and 6% in those taking 8 mg/day.
`Table 1 lists adverse events, regardless of causality, that were reported in the combined Phase 3, randomized,
`placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with Toviaz
`4 or 8 mg once daily for up to 12 weeks.
`
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 4
`
`

`

`Table 1: Adverse events with an incidence exceeding the placebo rate and reported by
`≥1% of patients from double-blind, placebo-controlled Phase 3 trials of 12 weeks
`treatment duration
`
`System organ class/Preferred term
`
`Placebo
`N=554
`%
`
`Toviaz
`
`4 mg/day
`N=554
`%
`
`Toviaz
`
`8 mg/day
`N=566
`%
`
`
`
`Gastrointestinal disorders
`
`
`18.8
`7.0
`Dry mouth
`4.2
`2.0
`Constipation
`1.6
`0.5
`Dyspepsia
`
`0.7
`1.3
`Nausea
`1.1
`0.5
`Abdominal pain upper
`Infections
`
`
`3.2
`3.1
`Urinary tract infection
`2.5
`2.2
`Upper respiratory tract infection
`Eye disorders
`
`
`1.4
`0
`Dry eyes
`Renal and urinary disorders
`
`
`1.3
`0.7
`Dysuria
`1.1
`0.2
`Urinary retention
`Respiratory disorders
`
`
`1.6
`0.5
`Cough
`0.9
`0.4
`Dry throat
`General disorders
`
`
`0.7
`0.7
`Edema peripheral
`Musculoskeletal disorders
`
`
`2.0
`0.4
`Back pain
`Psychiatric disorders
`
`
`1.3
`0.5
`Insomnia
`
`
`Investigations
`0.5
`0.9
`ALT increased
`0.4
`0.4
`GGT increased
`Skin disorders
`
`
`0.7
`0.5
`Rash
`ALT = alanine aminotransferase; GGT = gamma glutamyltransferase
`
`
`
`
`34.6
`6.0
`2.3
`1.9
`0.5
`
`4.2
`1.8
`
`3.7
`
`1.6
`1.4
`
`0.9
`2.3
`
`1.2
`
`0.9
`
`0.4
`
`1.2
`1.2
`
`1.1
`
`
`Patients also received Toviaz for up to three years in open-label extension phases of one Phase 2 and two Phase
`3 controlled trials. In all open-label trials combined, 857, 701, 529, and 105 patients received Toviaz for at least
`6 months, 1 year, 2 years, and 3 years, respectively. The adverse events observed during long-term, open-label
`studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth,
`constipation, dry eyes, dyspepsia, and abdominal pain. Similar to the controlled studies, most adverse events of
`dry mouth and constipation were mild to moderate in intensity. Serious adverse events, judged to be at least
`possibly related to study medication by the investigator and reported more than once during the open-label
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 5
`
`

`

`treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2
`cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).
`
`6.2 Post-marketing Experience: The following events have been reported in association with fesoterodine use
`
`in worldwide post-marketing experience: Eye disorders: Blurred vision; Cardiac disorders: Palpitations;
`General disorders and administrative site conditions: Hypersensitivity reactions, including angioedema with
`airway obstruction, face edema; Central nervous system disorders: Dizziness, headache, somnolence; Skin and
`subcutaneous tissue disorders: Urticaria, pruritus
`
`
`Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency
`of events and the role of fesoterodine in their causation cannot be reliably determined.
`
`7 DRUG INTERACTIONS
`
`
`
`7.1 Antimuscarinic Drugs: Coadministration of Toviaz with other antimuscarinic agents that produce dry
`mouth, constipation, urinary retention, and other anticholinergic pharmacological effects may increase the
`frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some
`
`concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.
`
`
`7.2 CYP3A4 Inhibitors: Doses of Toviaz greater than 4 mg are not recommended in patients taking potent
`CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin. Coadministration of the potent
`CYP3A4 inhibitor ketoconazole with fesoterodine led to approximately a doubling of the maximum
`
`concentration (Cmax) and area under the concentration versus time curve (AUC) of 5-hydroxymethyl tolterodine
`(5-HMT), the active metabolite of fesoterodine. Compared with CYP2D6 extensive metabolizers not taking
` ketoconazole, further increases in the exposure to 5-HMT were observed in subjects who were CYP2D6 poor
`
`
`
` metabolizers taking ketoconazole [see Clinical Pharmacology (12.3), Warnings and Precautions (5.8), and
`
` Dosage and Administration (2)].
`
`There is no clinically relevant effect of moderate CYP3A4 inhibitors on the pharmacokinetics of fesoterodine.
`Following blockade of CYP3A4 by coadministration of the moderate CYP3A4 inhibitor fluconazole 200 mg
`twice a day for 2 days, the average (90% confidence interval) increase in Cmax and AUC of the active
`metabolite of fesoterodine was approximately 19% (11% - 28%) and 27% (18% - 36%) respectively. No dosing
`adjustments are recommended in the presence of moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole,
`diltiazem, verapamil and grapefruit juice).
`
`The effect of weak CYP3A4 inhibitors (e.g. cimetidine) was not examined; it is not expected to be in excess of
`
`
`the effect of moderate inhibitors [see Clinical Pharmacology (12.3), Warnings and Precautions (5.8), and
`
`Dosage and Administration (2)].
`
`7.3 CYP3A4 Inducers: No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as
`rifampin and carbamazepine. Following induction of CYP3A4 by coadministration of rifampin 600 mg once a
`day, Cmax and AUC of the active metabolite of fesoterodine decreased by approximately 70% and 75%,
`
`respectively, after oral administration of Toviaz 8 mg. The terminal half-life of the active metabolite was not
`changed.
`
`7.4 CYP2D6 Inhibitors: The interaction with CYP2D6 inhibitors was not tested clinically. In poor
`
`metabolizers for CYP2D6, representing a maximum CYP2D6 inhibition, Cmax and AUC of the active
`
`metabolite are increased 1.7- and 2-fold, resp ectively.
`
`No dosing adjustments are recommended in the presence of CYP2D6 inhibitors.
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 6
`
`

`

` 7.5 Drugs Metabolized by Cytochrome P450: In vitro data indicate that at therapeutic concentrations, the
`
`
` active metabolite of fesoterodine does not have the potential to inhibit or induce Cytochrome P450 enzyme
`
` systems [see Clinical Pharmacology (12.3)].
`
`
`
`7.6 Oral Contraceptives: In the presence of fesoterodine, there are no clinically significant changes in the
`plasma concentrations of combined oral contraceptives containing ethinyl estradiol and levonorgestrel [see
`
`Clinical Pharmacology (12.3)].
`
`7.7 Warfarin: A clinical study has shown that fesoterodine 8 mg once daily has no significant effect on the
`pharmacokinetics or the anticoagulant activity (PT/INR) of warfarin 25 mg. Standard therapeutic monitoring for
`warfarin should be continued [see Clinical Pharmacology (12.3)].
`
`7.8 Drug-Laboratory Test Interactions: Interactions between Toviaz and laboratory tests have not been
`studied.
`
`8 USE IN SPECIFIC POPULATIONS
`
`8.1 Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies using Toviaz in
`pregnant women.
`
`
`
`No dose-related teratogenicity was observed in reproduction studies performed in mice and rabbits. In mice at 6
`to 27 times the expected exposure at the maximum recommended human dose (MRHD) of 8 mg based on AUC
`(75 mg/kg/day, oral), increased resorptions and decreased live fetuses were observed. One fetus with cleft palate
`was observed at each dose (15, 45, and 75 mg/kg/day), at an incidence within the background historical range.
`In rabbits treated at 3 to 11 times the MRHD (27 mg/kg/day, oral), incompletely ossified sternebrae (retardation
`of bone development) were observed in fetuses. In rabbits at 9 to 11 times the MRHD (4.5 mg/kg/day,
`subcutaneous), maternal toxicity and incompletely ossified sternebrae were observed in fetuses (at an incidence
`within the background historical range). In rabbits at 3 times the MRHD (1.5 mg/kg/day, subcutaneous),
`decreased maternal food consumption in the absence of any fetal effects was observed. Oral administration of
`30 mg/kg/day fesoterodine to mice in a pre- and post-natal development study resulted in decreased body
`weight of the dams and delayed ear opening of the pups. No effects were noted on mating and reproduction of
`the F1 dams or on the F2 offspring.
`
`
`
`Toviaz should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
`
`8.3 Nursing Mothers: It is not known whether fesoterodine is excreted in human milk. Toviaz should not be
`administered during nursing unless the potential benefit outweighs the potential risk to the neonate.
`
`
`
`
`8.4 Pediatric Use: The pharmacokinetics of fesoterodine have not been evaluated in pediatric patients.
`
`The safety and effectiveness of Toviaz in pediatric patients have not been established.
`
`
`8.5 Geriatric Use: No dose adjustment is recommended for the elderly. The pharmacokinetics of fesoterodine
`are not significantly influenced by age.
`Of 1567 patients who received Toviaz 4 mg/day or 8 mg/day in the Phase 2 and 3, placebo-controlled, efficacy
`and safety studies, 515 (33%) were 65 years of age or older, and 140 (9%) were 75 years of age or older. No
`overall differences in safety or effectiveness were observed between patients younger than 65 years of age and
`those 65 years of age or older in these studies; however, the incidence of antimuscarinic adverse events,
`including dry mouth, constipation, dyspepsia, increase in residual urine, dizziness (at 8 mg only) and urinary
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 7
`
`

`

`
`
` tract infection, was higher in patients 75 years of age and older as compared to younger patients [see Clinical
`
`
` Studies (14) and Adverse Reactions (6)].
`
`8.6 Renal Impairment: In patients with severe renal impairment (CLCR < 30 mL/min), Cmax and AUC are
`increased 2.0- and 2.3-fold, respectively. Doses of Toviaz greater than 4 mg are not recommended in patients
`with severe renal impairment. In patients with mild or moderate renal impairment (CLCR ranging from
`
`30-80 mL/min), Cmax and AUC of the active metabolite are increased up to 1.5- and 1.8-fold, respectively, as
`compared to healthy subjects. No dose adjustment is recommended in patients with mild or moderate renal
`
`
` impairment [see Warnings and Precautions (5.7) and Dosage and Administration (2)].
`
`8.7 Hepatic Impairment: Patients with severe hepatic impairment (Child-Pugh C) have not been studied;
`therefore Toviaz is not recommended for use in these patients. In patients with moderate (Child-Pugh B) hepatic
`impairment, Cmax and AUC of the active metabolite are increased 1.4- and 2.1-fold, respectively, as compared
`to healthy subjects. No dose adjustment is recommended in patients with mild or moderate hepatic impairment
`
` [see Warnings and Precautions (5.6) and Dosage and Administration (2)].
`
`
`8.8 Gender: No dose adjustment is recommended based on gender. The pharmacokinetics of fesoterodine are
`not significantly influenced by gender.
`
`8.9 Race: Available data indicate that there are no differences in the pharmacokinetics of fesoterodine between
`Caucasian and Black healthy subjects following administration of Toviaz.
`
`
`
`10 OVERDOSAGE
`
`Overdosage with Toviaz can result in severe anticholinergic effects. Treatment should be symptomatic and
`supportive. In the event of overdosage, ECG monitoring is recommended.
`
`
`11 DESCRIPTION
`
`Toviaz contains fesoterodine fumarate and is an extended-release tablet. Fesoterodine is rapidly de-esterified to
`its active metabolite (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, or 5-hydroxymethyl
`tolterodine, which is a muscarinic receptor antagonist.
`Chemically, fesoterodine fumarate is designated as isobutyric acid 2-((R)-3-diisopropylammonium-1­
`phenylpropyl)-4-(hydroxymethyl) phenyl ester hydrogen fumarate. The empirical formula is C30H41NO7 and its
`molecular weight is 527.66. The structural formula is:
`
`The asterisk (*) indicates the chiral carbon.
`Fesoterodine fumarate is a white to off-white powder, which is freely soluble in water. Each Toviaz
`extended-release tablet contains either 4 mg or 8 mg of fesoterodine fumarate and the following inactive
`
`
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 8
`
`

`

`ingredients: glyceryl behenate, hypromellose, indigo carmine aluminum lake, lactose monohydrate, soya
`lecithin, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and xylitol.
`
`12 CLINICAL PHARMACOLOGY
`
`
`12.1 Mechanism of Action: Fesoterodine is a competitive muscarinic receptor antagonist. After oral
`
`administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active
`metabolite, 5-hydroxymethyl tolterodine, which is responsible for the antimuscarinic activity of fesoterodine
`and is also one of the active moieties of tolterodine tartrate tablets and tolterodine tartrate extended-release
`capsules.
`Muscarinic receptors play a role in contractions of urinary bladder smooth muscle and stimulation of salivary
`
`secretion. Inhibition of these receptors in the bladder is presumed to be the mechanism by which fesoterodine
`produces its effects.
`
`12.2 Pharmacodynamics: In a urodynamic study involving patients with involuntary detrusor contractions, the
`effects after the administration of fesoterodine on the volume at first detrusor contraction and bladder capacity
`were assessed. Administration of fesoterodine increased the volume at first detrusor contraction and bladder
`capacity in a dose-dependent manner. These findings are consistent with an antimuscarinic effect on the
`bladder.
`Cardiac Electrophysiology: The effect of fesoterodine 4 mg and 28 mg on the QT interval was evaluated in a
`
`double-blind, randomized, placebo- and positive-controlled (moxifloxacin 400 mg once a day) parallel trial with
`once-daily treatment over a period of 3 days in 261 male and female subjects aged 44 to 65 years.
`Electrocardiographic parameters were measured over a 24-hour period at pre-dose, after the first administration,
`and after the third administration of study medication. Fesoterodine 28 mg was chosen because this dose, when
`administered to CYP2D6 extensive metabolizers, results in an exposure to the active metabolite that is similar
`to the exposure in a CYP2D6 poor metabolizer receiving fesoterodine 8 mg together with CYP3A4 blockade.
`Corrected QT intervals (QTc) were calculated using Fridericia’s correction and a linear individual correction
`method. Analyses of 24-hour average QTc, time-matched baseline-corrected QTc, and time-matched placebo-
`subtracted QTc intervals indicate that fesoterodine at doses of 4 and 28 mg/day did not prolong the QT interval.
`The sensitivity of the study was confirmed by positive QTc prolongation by moxifloxacin.
`Toviaz is associated with an increase in heart rate that correlates with increasing dose. In the study described
`above, when compared to placebo, the mean increase in heart rate associated with a dose of 4 mg/day and 28
`mg/day of fesoterodine was 3 beats/minute and 11 beats/minute, respectively.
`In the two, phase 3, placebo-controlled studies in patients with overactive bladder, the mean increase in heart
`rate compared to placebo was approximately 3-4 beats/minute in the 4 mg/day group and 3-5 beats/minute in
`the 8 mg/day group.
`
`
`
`12.3 Pharmacokinetics:
`
`Absorption: After oral administration, fesoterodine is well absorbed. Due to rapid and extensive hydrolysis by
`nonspecific esterases to its active metabolite 5-hydroxymethyl tolterodine, fesoterodine cannot be detected in
`
` plasma. Bioavailability of the active metabolite is 52%. After single or multiple-dose oral administration of
`fesoterodine in doses from 4 mg to 28 mg, plasma concentrations of the active metabolite are proportional to the
`dose. Maximum plasma levels are reached after approximately 5 hours. No accumulation occurs after
`multiple-dose administration.
`A summary of pharmacokinetic parameters for the active metabolite after a single dose of Toviaz 4 mg and
`8 mg in extensive and poor metabolizers of CYP2D6 is provided in Table 2.
`
`Reference ID: 3168116
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1024 - Page 9
`
`

`

`Table 2: Summary of geometric mean [CV] pharmacokinetic parameters for the active metabolite after a
`single dose of Toviaz 4 mg and 8 mg in extensive and poor CYP2D6 metabolizers
`Toviaz 4 mg
`Toviaz 8 mg
`EM (n=16)
`EM (n=16)
`1.89 [43%]
`3.98 [28%]
`21.2 [38%]
`45.3 [32%]
`
`
`Parameter
`Cmax (ng/mL)
`AUC0-tz
`(ng*h/mL)
`tmax (h)a
`5 [5-6]
`5 [3-6]
`5 [5-6]
`5 [2-6]
`t½ (h)
`7.66 [21%]
`8.59 [41%]
`7.31 [30%]
`7.31 [27%]
`EM = extensive CYP2D6 metabolizer, PM = poor CYP2D6 metabolizer, CV = coefficient of variation
`Cmax = maximum plasma concentration, AUC0-tz = area under the concentration time curve from zero up to the
`
` last measurable plasma concentration , tmax = time to reach Cmax, t½ = terminal half-life
`a Data presented as median (range)
`
`Effect of Food: There is no clinically relevant effect of food on the pharmacokinetics of fesoterodine. In a
` study of the effects of food on the pharmacokinetics of fesoterodine in 16 healthy male volunteers, concomitant
`
`food intake increased the active metabolite of fesoterodine AUC by approximately 19% and Cmax by 18% [see
`
` Dosage and Administration (2)].
`
`
` Distribution: Plasma protein binding of the active metabolite is low (approximately 50%) and is primaril y
`
`bound to albumin and alpha-1-acid glycoprotein. The m ean steady-state volume of distribution following
`intravenous infusion of the active metabolite is 169 L.
`
`Metabolism: After oral administration, fesoterodine is rapidly and extensively hydrolyzed to its active
`metabolite. The active metabolite is further metabolized in the liver to its carboxy, carboxy-N-desisopr opyl, and
`N-desisopropyl metabolites via two major pathways involving CYP2D6 and CYP3A 4. None of these
`metabolites contribute significantly to the antimuscarinic activity of fesoterodine.
`Variability in CYP2D6 Metabolism: A subset of individuals (approximately 7% of Caucasians and
`approximately 2% of African Americans) are poor metabolizers for CYP2D6. Cmax and AUC of the active
`metabolite are increased 1.7- and 2-fold, respectively, in CYP2D6 poor metabolizers, as compared to extensive
`
` metabolizers.
`
`Excretion: Hepatic metabolism and renal excretion contribute significantly to the elimination of the ac tive
`metabolite. After oral administration of fesoterodine, approximately 70% of the administered dose was
`recovered in urine as the active metabolite (16%), carboxy metabolite (34%), carboxy-N-desisopropyl
`metabolite (18%), or N-desisopropyl metabolite (1%), and a smaller amount (7%) was recovered in feces.
`The terminal half-life of the active metabolite is approximately 4 hours following an intr avenous administration.
`The apparent terminal half-life following oral administration is approximately 7 hours.
`
`Pharmacokinetics in Specific Populations:
`
`
`PM (n=8)
`3.45 [54%]
`40.5 [31%]
`
`PM (n=8)
`6.90 [39%]
`88.7 [36%]
`
`
`
`Geriatric Patients: Following a single 8 mg oral dose of fesoterodine, the mean (±SD) AUC and Cmax for the
`
`active metabolite 5-hydroxymethyl tolterodine in 12 elderly men (mean age 67 years) were 51.8 ± 26.1
`h*ng/mL and 3.8 ± 1.7 ng/mL, respectively. In the same

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket